Abstract
Background: Despite evidence of their benefit and efforts to increase usage, anticoagulation for stroke prophylaxis in atrial fibrillation (AF) patients remains underutilized. Previous surveys have assessed reasons for underuse of anticoagulation but have limitations including non-structured approach for eliciting barriers and use of clinical vignettes and not patient-level data. The objectives of this study were to develop a questionnaire to assess barriers to anticoagulation use for stroke prophylaxis in AF patients at a patient- and physician-level and to conduct a preliminary field-test of the instrument.
Methods: Barriers to warfarin use were identified from a literature review, input from clinical experts, and a physician focus group. A sample of US physicians who treat AF patients completed the questionnaire. Physicians ranked their reluctance on a 1–10 scale (10 = very reluctant) in general to prescribe warfarin if a specific barrier was present in a patient and then indicated critical barriers to prescribing warfarin in a sample of their own AF patients not receiving warfarin.
Results: Forty-one barriers to warfarin use were identified and classified into 4 groups: patient medical characteristics (n = 17), health care system factors (n = 7), patient capability (n = 12), and patient preferenc (n = 5). Several new items were developed (e.g., difficulty in obtaining venous access), existing items were revised (e.g., timeframe for bleeding episodes subdivided into > or ≤ 3 months), and multi-factorial barriers (e.g., dementia, epilepsy) were explored. The factor that most strongly influenced physicians' (n = 30) decisions not to prescribe warfarin was severe bleeding < 3 months ago (mean ± SD: 9.2 ± 1.3) while the most prevalent critical barriers to prescribing warfarin in specific AF patients (n = 24) was patient unwilling to undergo repeat testing (29%).
Conclusion: This questionnaire has the potential to assist in better understanding barriers to warfarin use with a view to addressing and then overcoming warfarin underutilization. Preliminary data suggest patient preference and capabilities are at least as important as medical characteristics as barriers to prescribing warfarin in AF patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Atrial fibrillation as a contributing cause of death and Medicare hospitalization – United States, 1999. MMWR 2003;52:128–131.
American Heart Association. Heart Disease and Stroke Statistics – 2005 Update. Dallas, TX: American Heart Association 2005.
Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation: developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001;38:1231– 1266.
Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492–501.
Bradley BC, Perdue KS, Tisdel KA, Gilligan DM. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol 2000;85:568–572.
Scott PA, Pancioli AM, Davis LA, Frederiksen SM, Eckman J. Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients. Stroke 2002;33:2664–2669.
Adhiyaman V, Kamalakannan D, Oke A, Shah IU, White AD. Underutilization of antithrombotic therapy in atrial fibrillation. J R Soc Med 2000;93:138–140.
Jackson SL, Peterson GM, Vial JH. A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation. Ann Pharmacother 2004;38:1794–1799.
Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998;97:1231–1233.
Bungard TJ, Ghali WA, McAlister FA, Buchan AM, Cave AJ, Hamilton PG, et al. Physicians’ perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation. CMAJ 2001;165:301–302.
Bungard TJ, Ghali WA, McAlister FA, Buchan AM, Cave AJ, Hamilton PG, et al. The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Can J Cardiol 2003;19:280–284.
Monette J, Gurwitz JH, Rochon PA, Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc 1997;45:1060–1065.
Peterson GM, Boom K, Jackson SL, Vial JH. Doctors’ beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Intern Med J 2002;32:15–23.
Gross CP, Vogel EW, Dhond AJ, Marple CB, Edwards RA, Hauch O, et al. Factors influencing physicians’ reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther 2003;25:1750–1764.
Pradhan AA, Levine MA. Warfarin use in atrial fibrillation: A random sample survey of family physician beliefs and preferences. Can J Clin Pharmacol 2002;9:199–202.
Buckingham TA, Hatala R. Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol 2002;25:447–454.
Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41–46.
Samsa G, Matchar DB, Dolor RJ, Wiklund I, Hedner E, Wygant G, et al. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes 2004;2:22.
McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277–281.
Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001;323:1218–1222.
Moroney JT, Tseng CL, Paik MC, Mohr JP, Desmond DW. Treatment for the secondary prevention of stroke in older patients: the influence of dementia status. J Am Geriatr Soc 1999;47:824–829.
Barcellona D, Contu P, Sorano GG, Pengo V, Marongiu F. The management of oral anticoagulant therapy: the patient’s point of view. Thromb Haemost 2000;83:49– 53.
Putnam W, Nicol K, Anderson D, Brownell B, Chiasson M, Burge FI, et al. Anticoagulation in atrial fibrillation. Is there a gap in care for ambulatory patients? Can Fam Physician 2004;50:1244–1250.
Man-Son-Hing M, Laupacis A, O’Connor A, Wells G, Lemelin J, Wood W, et al. Warfarin for atrial fibrillation. The patient’s perspective. Arch Intern Med. 1996;156:1841–1848.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ingelgård, A., Hollowell, J., Reddy, P. et al. What are the barriers to warfarin use in atrial fibrillation?: Development of a questionnaire. J Thromb Thrombolysis 21, 257–265 (2006). https://doi.org/10.1007/s11239-006-5633-2
Issue Date:
DOI: https://doi.org/10.1007/s11239-006-5633-2